Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2

Breast Cancer Research and Treatment

Volumn 125, Issue 1, 2011, Pages 89-97

  Zhang, Kai Xin ^a   Kim, Connie ^a   Chow, Elaine ^a   Chen, Irvin S Y ^b   Jia, William ^c   Rennie, Paul S ^a,d  

^a VANCOUVER PROSTATE CENTRE   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bioluminescence imaging; Breast cancer; Circulating cancer cells; HER 2; Lentivirus; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; ENHANCED GREEN FLUORESCENT PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANCICLOVIR; LENTIVIRUS VECTOR; LUCIFERASE; THYMIDINE KINASE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BREAST CANCER; CANCER CELL; CELL KILLING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; GENETIC ENGINEERING; HERPES SIMPLEX; HUMAN; HUMAN CELL; IN VIVO STUDY; LENTIVIRINAE; LOW DRUG DOSE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; NUDE MOUSE; OVERALL SURVIVAL; PRIORITY JOURNAL; SINDBIS VIRUS; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GANCICLOVIR; GENE THERAPY; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; LENTIVIRUS; LUCIFERASES; MICE; MICE, NUDE; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2; THYMIDINE KINASE;

EID: 78651066250     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0828-9     Document Type: Article

References (39)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 10.3322/caac.20006 19474385
2. EE Lower E Glass R Blau, et al. 2009 HER-2/neu expression in primary and metastatic breast cancer Breast Cancer Res Treat 113 301 306 1:CAS:528:DC%2BD1MXhsVKntA%3D%3D 10.1007/s10549-008-9931-6 18273700
3. G Riou MC Mathieu M Barrois, et al. 2001 c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients Int J Cancer 95 266 270 1:CAS:528:DC%2BD3MXlt1yqsrc%3D 10.1002/1097-0215(20010720)95:4<266::AID- IJC1045>3.0.CO;2-E 11400121 (Pubitemid 32592095)
4. W Hanna HJ Kahn M Trudeau 1999 Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside Mod Pathol 12 827 834 1:STN:280: DyaK1MzptFWhtQ%3D%3D 10463486
5. DJ Slamon GM Clark SG Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 1:CAS:528:DyaL2sXhtVSht7s%3D 10.1126/science.3798106 3798106
6. EP Winer HJ Burstein 2001 New combinations with Herceptin in metastatic breast cancer Oncology 61 Suppl 2 50 57 1:CAS:528:DC%2BD3MXovFWjsLk%3D 10.1159/000055402 11694788 (Pubitemid 33033425)
7. J Baselga 2001 Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials Oncology 61 Suppl 2 14 21 1:CAS:528:DC%2BD3MXovFWjsL0%3D 10.1159/000055397 11694783
8. MD Pegram DJ Slamon 1999 Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity Semin Oncol 26 89 95 1:CAS:528: DyaK1MXmt1Sitr8%3D 10482199
9. MA Cobleigh CL Vogel D Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
10. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
11. S Braun B Naume 2005 Circulating and disseminated tumor cells J Clin Oncol 23 1623 1626 10.1200/JCO.2005.10.073 15755968 (Pubitemid 46211415)
12. T Dull R Zufferey M Kelly, et al. 1998 A third-generation lentivirus vector with a conditional packaging system J Virol 72 8463 8471 1:CAS:528:DyaK1cXmslaisbc%3D 9765382
13. K Morizono Y Xie GE Ringpis, et al. 2005 Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection Nat Med 11 346 352 1:CAS:528:DC%2BD2MXhvVSru7s%3D 10.1038/nm1192 15711560 (Pubitemid 40460565)
14. F Aires da Silva MJ Costa S Corte-Real, et al. 2005 Cell type-specific targeting with Sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies Hum Gene Ther 16 223 234 1:CAS:528:DC%2BD2MXitFCgsLs%3D 10.1089/hum.2005.16.223 15761262 (Pubitemid 40344214)
15. K Morizono G Bristol YM Xie, et al. 2001 Antibody-directed targeting of retroviral vectors via cell surface antigens J Virol 75 8016 8020 1:CAS:528:DC%2BD3MXmtFejtLg%3D 10.1128/JVI.75.17.8016-8020.2001 11483746 (Pubitemid 32743673)
16. WB Klimstra JC Williams KD Ryman, et al. 2005 Targeting Sindbis virus-based vectors to Fc receptor-positive cell types Virology 338 9 21 1:CAS:528:DC%2BD2MXlsVChsLc%3D 10.1016/j.virol.2005.04.039 15922395 (Pubitemid 40835922)
17. N Pariente K Morizono MS Virk, et al. 2007 A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration Mol Ther 15 1973 1981 1:CAS:528:DC%2BD2sXhtFygtrzJ 10.1038/sj.mt.6300271 17653099 (Pubitemid 350011737)
18. R Nahta D Yu MC Hung, et al. 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 269 280 1:CAS:528:DC%2BD28Xltlagtbg%3D 10.1038/ncponc0509 16683005 (Pubitemid 43731112)
19. KX Zhang M Moussavi C Kim, et al. 2009 Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells Cancer Gene Ther 16 820 831 1:CAS:528:DC%2BD1MXks1Shsbg%3D 10.1038/cgt.2009.28 19373278
20. GA Niehans TP Singleton D Dykoski, et al. 1993 Stability of HER-2/neu expression over time and at multiple metastatic sites J Natl Cancer Inst 85 1230 1235 1:STN:280:DyaK3szitlWntw%3D%3D 10.1093/jnci/85.15.1230 8101229
21. CG Murphy S Modi 2009 HER2 breast cancer therapies: a review Biologics 3 289 301 1:CAS:528:DC%2BD1MXhsVyksb3N 19707416
22. GD King AK Muhammad W Xiong, et al. 2008 High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity J Virol 82 4680 4684 1:CAS:528:DC%2BD1cXltVOmuro%3D 10.1128/JVI.00232-08 18287240 (Pubitemid 351563707)
23. M Raki T Hakkarainen GJ Bauerschmitz, et al. 2007 Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus Gene Ther 14 1380 1388 1:CAS:528: DC%2BD2sXhtVCkurfL 10.1038/sj.gt.3302992 17611584 (Pubitemid 47423737)
24. KC Straathof DM Spencer RE Sutton, et al. 2003 Suicide genes as safety switches in T lymphocytes Cytotherapy 5 227 230 1:CAS:528:DC%2BD3sXmt1eqtb0%3D 10.1080/14653240310001497 12850790 (Pubitemid 37086766)
25. PT Golumbek FM Hamzeh EM Jaffee, et al. 1992 Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines J Immunother 12 224 230 1:STN:280:DyaK3s7itVSmtg%3D%3D 10.1097/00002371-199211000-00002 1335754
26. RL Touraine H Ishii-Morita WJ Ramsey, et al. 1998 The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication Gene Ther 5 1705 1711 1:CAS:528:DyaK1cXnvFOltb4%3D 10.1038/sj.gt.3300784 10023450
27. G Fulci L Breymann D Gianni, et al. 2006 Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses Proc Natl Acad Sci USA 103 12873 12878 1:CAS:528:DC%2BD28XptVymt74%3D 10.1073/pnas.0605496103 16908838 (Pubitemid 44298654)
28. G Fulci N Dmitrieva D Gianni, et al. 2007 Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses Cancer Res 67 9398 9406 1:CAS:528:DC%2BD2sXhtFSnurrK 10.1158/0008-5472.CAN-07-1063 17909049 (Pubitemid 47535930)
29. Z Borok JE Harboe-Schmidt SL Brody, et al. 2001 Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells J Virol 75 11747 11754 1:CAS:528:DC%2BD3MXotlaqsL8%3D 10.1128/JVI.75.23.11747-11754.2001 11689655 (Pubitemid 33063265)
30. T Schnell P Foley M Wirth, et al. 2000 Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus Hum Gene Ther 11 439 447 1:CAS:528:DC%2BD3cXht1Gktb8%3D 10.1089/10430340050015905 10697118 (Pubitemid 30101953)
31. R Cattaneo T Miest EV Shashkova, et al. 2008 Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded Nat Rev Microbiol 6 529 540 1:CAS:528:DC%2BD1cXntFOrt7o%3D 10.1038/nrmicro1927 18552863 (Pubitemid 351850977)
32. DJ Slamon 1990 Studies of the HER-2/neu proto-oncogene in human breast cancer Cancer Invest 8 253 1:STN:280:DyaK3czotFGkug%3D%3D 10.3109/ 07357909009017573 1976032
33. S Paik R Hazan ER Fisher, et al. 1990 Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer J Clin Oncol 8 103 112 1:STN:280:DyaK3c7htFOktw%3D%3D 1967301
34. SA Eccles 2001 The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis J Mammary Gland Biol Neoplasia 6 393 406 1:STN:280: DC%2BD383ntVGmug%3D%3D 10.1023/A:1014730829872 12013529 (Pubitemid 39600497)
35. R Nahta T Takahashi NT Ueno, et al. 2004 P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 3981 3986 1:CAS:528:DC%2BD2cXksVKns7k%3D 10.1158/0008-5472.CAN-03-3900 15173011 (Pubitemid 38697313)
36. I Bergman P Whitaker-Dowling Y Gao, et al. 2003 Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells Virology 316 337 347 1:CAS:528:DC%2BD3sXpsVSlt78%3D 10.1016/j.virol.2003.07.010 14644615 (Pubitemid 37468536)
37. BA Hadaschik K Zhang AI So, et al. 2008 Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer Urologe A 47 1145 1151 1:STN:280:DC%2BD1crnvFSnsQ%3D%3D 10.1007/s00120-008-1827- x 18670747
38. BA Hadaschik K Zhang AI So, et al. 2008 Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer Cancer Res 68 4506 4510 1:CAS:528:DC%2BD1cXnt1aqsb0%3D 10.1158/0008-5472.CAN- 08-0238 18559493
39. GD Lewis Phillips G Li DL Dugger, et al. 2008 Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 9280 9290 1:CAS:528:DC%2BD1cXhtlOmt7rK 10.1158/0008-5472.CAN-08-1776 19010901